

Targeting Immune Cells in the Tumor Microenvironment: Molecular Mechanisms and Emerging Therapeutics

*Kanaka Durga Devi Nelluri, S. Siva Sri, T. Bhargavi Krishna, V. Teja Sri, Y. Sharon
Satwika Christina, Minakshi Kommoju

Kvsr Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.

Corresponding email: nellurikvsr22@gmail.com

ABSTRACT: Tumor microenvironment (TME) is a complex network made up of cancer cells, supportive components such as immune cells, stromal components, soluble signaling molecules, and the extracellular matrix (ECM). These different components communicate and are essential for supporting or inhibiting tumor development, metastasis, evasion of the immune system, and resistance to therapy. In this landscape, there are several immune cells that assist or damage tumor growth according to many different internal cues. The important players in this immune environment are cytotoxic and helper T cells, dendritic cells, and suppressive cells like regulatory T cells and myeloid-derived suppressor cells. Immune suppression and immune evasion are created by cancer cells by using the immune checkpoint mechanisms, particularly PD1/PD-L1 and CTLA-4. The immune microenvironment is also defined by modulatory signaling molecules like cytokines and chemokines based on immune cell behaviour and metabolic alterations in the TME. Although a number of immunotherapies, including checkpoint blockade, cancer vaccines, and cell-based therapies, have been effectively applied to patients, tumor resistance remains an issue. We are also investigating a plethora of innovative possibilities to enhance treatment specificity and broaden immune activation with new agents in nanomedicine, cancer vaccine neoantigens and artificial intelligence. While molecular diagnostics are now increasingly utilized including next-generation sequencing and liquid biopsies to tailor therapies, the hope for enhancing cancer outcomes still lingers. Nevertheless, numerous challenges.

KEYWORDS: Tumor microenvironment, immune cells, stromal components, metastasis, cytotoxic cells, helper T cells, modulating signaling molecules, cytokines, chemokines, immunotherapy, nanomedicine.

INTRODUCTION

Tumor microenvironment (TME) is today extensively recognized as a determinant of cancer behaviour and therapeutic response. It consists not only of malignant cells but also of a heterogeneous population of non-neoplastic cells like stromal cells, immune cells, blood vessels, signaling molecules, and the extracellular matrix (ECM). These parts interact with each other continuously to control tumor development, expansion, and drug resistance. Among these, immune cells have a unique function, in that they can suppress and promote tumor growth depending on context and regulatory signals within the TME (1).

OVERVIEW OF THE TUMOR MICROENVIRONMENT (TME)

The tumor microenvironment (TME) plays an important role in influencing the cancer growth its ability to spread and how effectively it responds to the treatment. The tumour microenvironment (TME) is more than just a place where cancer grows and it is a complex network of cells, molecules, structures that surround and interacts with the tumor cells. This environment includes immune cells, fibroblasts, blood vessels, extracellular matrix (ECM) proteins, chemical signals like cytokines and growth factors. Unlike healthy tissues, the TME is usually low in oxygen (hypoxia), highly


acidic and rich in inflammatory and immunosuppressive signals. These abnormal conditions create an environment where tumors can grow more aggressively, spread to other parts of the body and become resistant to the therapy. At the same time it directly affects the functioning of immune cells, how blood vessels form and how drugs are delivered(2).

COMPOSITION OF THE TUMOR MICRO ENVIRONMENT (TME)

The tumor microenvironment (TME) is a highly interactive network that supports and shapes tumor behaviour. It is composed of multiple cellular and non-cellular components each playing distinct roles in cancer development, immune evasion and therapy response. It consists of both malignant and non-malignant elements that actively influence cancer progression. Core components include tumor, stromal, vascular, immune cells, soluble factors and ECM.

- Tumor cells: Exhibit genetic instability and releases factors that shape the surrounding environment. It stimulates oncogenic growth and prolong tumor cell viability. Exhibits genetic and phenotypic diversity contributing to tumor heterogeneity.

- **Stromal cells:** These non immune support cells shape the tumor's physical and chemical environment. Mainly cancer-associated fibroblasts (CAFs), which remodel the extracellular matrix and regulate immune responses(3,4). Endothelial Cells forms abnormal leaky blood vessels which leads to hypoxia, uneven delivery of immune cells and therapies. Pericytes support vascular structure and stability and interact with endothelial cells and influence angiogenesis.
- **Immune cells:** Divided into anti-tumor and pro-tumor (immunosuppressive) types.
- **Anti-Tumor Immune Cells:** CD8⁺ T cells, NK cells, dendritic cells



initiate and sustain immune attack.

Figure 1. Composition of the Micro environment

- **Immunosuppressive Immune Cells:** Tregs, MDSCs, M2-polarized TAMs suppress immune

responses and promote tumor progression.

HETEROGENEITY OF THE TME ACROSS CANCER TYPES

One of the reasons cancer is so hard to treat is because no two tumors are exactly the same not even in the same person. The TME varies not just between different types of cancer but also within the same tumor. This is called heterogeneity.

In some cancers like melanoma or lung cancer the TME is rich in immune cells which may make them more responsive to immunotherapy. In others, like pancreatic or prostate cancer, the tumor is surrounded by thick layers of fibrous tissue and suppressive cells that block immune access. Even within a single tumor, some areas might be inflamed and immune-active, while others remain “cold” and inaccessible. This diversity affects how tumors grow, spread and respond to treatment and is one of the major challenges in designing effective therapies. Types include Inter-Tumoral, Intra-Tumoral, Temporal (5).

TUMOR–IMMUNE SYSTEM INTERACTIONS

The immune system is constantly on the lookout for abnormal cells, including early cancer cells. Ideally, it detects and destroys

them before they become dangerous. But tumors are clever. Over time, they learn how to hide from the immune system or shut it down. Some of the tricks tumors use include:

- Putting up molecular “stop signs” (like PD-L1) to block attacking T cells.
- Recruiting suppressive immune cells that silence anti tumor fighters.
- Releasing signals that cause inflammation or exhaustion in helpful immune cells.
- This back-and-forth interaction between the tumor and immune system is often referred to as an “immune escape.” Understanding how these interactions work helps researchers design therapies that remove the brakes and empower the immune system to fight back (6).

KEY IMMUNE CELLS IN THE TME AND THEIR ROLES

Inborn immune cells in tumor Microenvironment involves an important role in the existence and growth of the tumor, and this also shows a double effect by promoting tumor and also by inhibition of tumor under different microenvironments and stimulations. The formation of tumors is known as tumorigenesis. Innate immune cells play an

essential role in shaping the environment around tumors, and their influence has driven the development of forward-thinking cancer treatments. Scientists are focused on boosting the natural strength of these cells while breaking down the immune-suppressive shield that tumors often build. The strategies vary widely: from immune checkpoint inhibitors that block key signaling pathways, to immune-enhancing agents like STING and CD40 that rev up cellular responses (7).

T LYMPHOCYTES:

T cells are kind of WBC cells, so they are known as lymphocytes. Hence they are named as T lymphocytes. these lymphocytes helps us to fight with germs and also protect us from diseases by destroying the infected cells.

Types of T Cells:

- Cytotoxic T cells: These cells directly target and destroy virus-infected cells, bacteria-infected cells, and tumor cells. They recognize threats and eliminate compromised cells through their CD8 surface receptors.
- Helper T cells: Instead of expiring the cells, they keep the immune response in an order. Using CD4 receptors, they send signals to

activate cytotoxic T cells, B cells, and macrophages to fight against pathogens.

MOLECULAR PATHWAYS REGULATING IMMUNE CELL FUNCTION IN THE TME

The tumor microenvironment (TME) is evolving and adaptable environment that has a transformative effect on how immune cells work, eventually influence how cancer grows and habituate to the treatment. This environment is formed by a complex web of molecular signals that navigate conveying between cells, activate different types of signaling events, and drive metabolic shifts. Together, these procedure cast the immune atmosphere within tumors. Here's a complete view of the main action and mechanisms at play: Cytokines and chemokines are the intimating proteins that help collaboration the body immune defenses. When their normal balance is disrupted, it can trigger inflammation and damage in both the CNS and PNS . This imbalance plays a major role in conditions like degradation of nerve tissue, and the decrease of protective myelin around nerves—also seen in chronic pain disorders (8).

IMMUNE CHECKPOINT PATHWAYS: PD-1/PD-L1, CTLA-4:

Fatigue and a feeling of weakness are among the most frequent complaints made by patients on ICIs. However, these might just be the immediate effects of therapies like anti-PD-1 or anti-CTLA-4. Adopting a holistic perspective of the patient is becoming more and more important in cancer care. In cancer care, adopting all inclusive view of the patient is becoming most essential. This stand point is particularly salient feature with the enlargement use of immune checkpoint inhibitors which , while productive, can lead to obstacles affecting various organs. For clinicians,even in the known about the wide-ranging immune-related adverse side effects is key. It employs them to make better treatment resolution, forecast possible issues, acknowledging symptoms early, and intercede appropriately to support the patient's whole comfort and welfare (9).

MECHANISMS OF IMMUNE EVASION IN THE TME

tumour cells are exceptional adept at avoiding the demolition by the immune system, often utilize their local environment to do so. A crucial get away route involves hijacking immune checkpoints mechanisms that commonly keep immune reactions in check. Tumors often construct a antagonistic environment that protects them from the immune system.

One strategy they use is to involve with immune checkpoints like PD-1/PD-L1 pathway which modulate the activity of T cells, allowing cancer to develop without resistance. In addition, cancer cells give rise to substances like IL-10, and VEGF that assist the growth of suppressed immune cell types, involving regulatory T cells and myeloid-derived suppressor cells (MDSCs). These cells declare toxic signals, like reactive oxygen species, then additionally weaken the immune response and control the capacity of T cells to fight the cancer cells (10).

IMMUNE EDITING AND ANTIGEN LOSS:

A remarkable yet often unnoticed barrier in cancer immunotherapy lies in its dependence on antigen-specific immune activity. In spite of targeting tumor-specific markers has shown potential ability, this approach is perforated with many complications. Immunotherapy is now vigorously promoted as a confront tool in the fight against cancer. Beginning studies reveals its ability to mdeploy the immune system against metastatic disease. Yet, converting those vigorous results from laboratory models into consonent success in clinical settings has proven demanding , even though some therapies have shown significant effect (11).

THERAPEUTIC STRATEGIES TARGETING IMMUNE CELLS IN THE TME

IMMUNE CHECKPOINT INHIBITORS:

Immune checkpoints are also crucial in our immune response, and they assist in controlling the immune reactions and preventing healthy cells from being inadvertently targeted. Checkpoints work by protein expression on T cells binding to their respective counterpart proteins on other cells, such as some cancer cells. [Refer to Figure 2] Once the proteins bind, they tell the T cells to "shut down," which can decrease their activity. This opens up a window of opportunity for tumors to evade immune detection. Checkpoint inhibitors break this process belongs to immunotherapy. Immune checkpoint inhibitors work by blocking proteins like CTLA-4, PD-1, or its partner PD-L1. This action helps to lift the brakes on T cell activity, allowing the immune system to look for and demolish cancer cells effectively. Determined tumors take advantage of this pathway by producing excessive PD-L1 to suppress the immune response(12).




Figure 2. Immune checkpoint inhibitors work against cancer

CANCER VACCINES AND DENDRITIC CELL THERAPY:

Anticancer vaccines were initially primarily constructed to be cancer prevention vaccines. Nowadays, we see the advent of therapeutic cancer vaccines, which are a new type of immunotherapy to enhance the immune system of the host against established tumors. They are very promising, particularly for advanced or refractory cancer patients, since they are capable of eliciting immune responses to specifically kill tumors. They employ multiple sources in making these vaccines, such as whole tumor cells, tumor lysates, genetically modified cells, and tumor-associated antigens (TAAs) in form of peptides or proteins, and nucleic acids and cancer cells engineered to produce immune-stimulating cytokines. Whole tumor cell vaccines are also divided into autologous (derived from the patient) and

allogenic (derived from donors). For instance, Sipuleucel-T is an autologous cell-based cancer immunotherapy that was approved in 2010. Though the detailed mechanism is unknown, it is thought to educate the patient's antigen-presenting cells (APCs) to recognize and react against prostatic acid phosphatase (PAP), a protein indicated in prostate cancer cells(13).

EMERGING MOLECULAR TOOLS AND TECHNOLOGIES

NANOTECHNOLOGY AND IMMUNE MODULATION:

The increasing significance of nanotechnology in improving the future of cancer immunotherapy is based on the ability to highly modify the immune system and re-educate the tumor microenvironment. With engineered nanoparticles now delivering immunotherapeutic products that include peptides, nucleic acids, immune checkpoint inhibitors, and immune-activating molecules, researchers are now delivering Immunotherapeutics into the immune cells of interest. These site-specific delivery outcomes are expanded, supporting key functions like antigen presentation, programming macrophages to fight the tumor, e.g., modifying the M1 phenotype, enhancement of dendritic cell differentiation, and improving T-cell

priming. Additionally, nanoparticles can allow for sustained drug release and limit system side effects, making them potential candidates for treatment with chemotherapy, phototherapy, or immune checkpoint blockade. Although preclinical studies and early clinical experience appear encouraging, suggesting possible abilities to reverse immune exhaustion and improve antitumor immunity, additional clinical studies will need to be conducted to demonstrate the feasibility and safety of the transition into the next acceptable standard of care(14).

CHALLENGES AND FUTURE PERSPECTIVES

OVERCOMING RESISTANCE TO IMMUNOTHERAPY:

Immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have revolutionized cancer therapy. Yet, many patients face primary resistance (no initial response) or acquired resistance (relapse after initial response). Causes include both tumor-intrinsic and tumor-extrinsic mechanisms tied to the tumor microenvironment (TME) (15).

PERSONALIZATION OF IMMUNO-ONCOLOGY STRATEGIES:

Modern immunotherapy is shifting toward precision medicine. Which helps customize

treatment, to each patient's tumor and immune profile.

Biomarkers for Personalization:

- PD-L1 expression
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- HLA typing and neoantigen prediction
- T cell receptor (TCR) diversity
- IFN- γ expression signature

Advanced Personalized Therapies:

1. Neoantigen Vaccines: For instance, mRNA-4157 + pembrolizumab reduced recurrence in melanoma patients by 44%.
2. Adoptive Cell Therapy (ACT): Includes TILs, CAR-T, and TCR-T. Notably, Lifileucel shows promise in PD-1 refractory melanoma (16).
3. AI in Immuno-Oncology: Assists in treatment recommendations, neoantigen prediction, and HLA binding analysis.

INTEGRATING MOLECULAR PROFILING INTO CLINICAL PRACTICE:

Molecular Profiling Technologies:

- NGS-based Comprehensive Genomic Profiling (CGP): Detects mutations (KRAS, BRAF, EGFR), MSI, TMB, and gene fusions (17).

- Liquid biopsy (ctDNA): Non-invasive, enables monitoring of treatment and minimal residual disease (MRD).
- Single-cell and spatial transcriptomics: Provides spatial insights into immune and stromal architecture (18,1,20).

within the TME enables the development of targeted and personalized treatments. Advances like molecular profiling, neoantigen vaccines, and CAR-T therapies hold great promise. Future strategies focusing on combination therapies and microbiome modulation may further improve clinical outcomes.

CONCLUSION

The tumor microenvironment (TME) significantly influences cancer development and the effectiveness of immunotherapy. Understanding the diverse immune cells and molecular pathways

ACKNOWLEDGEMENT

The authors sincerely express their gratitude to the management and principal of KVSRR Siddhartha College of Pharmaceutical Sciences, Vijayawada, for their continuous support and encouragement.

REFERENCES

1. Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell*, 21(3), 309–322. <https://doi.org/10.1016/j.ccr.2012.02.022>
2. Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*, 19(11), 1423–1437. <https://doi.org/10.1038/nm.3394>
3. Gajewski, T. F., Schreiber, H., & Fu, Y. (2013). Innate and adaptive immune cells in the tumor microenvironment. *Nature Immunology*, 14(10), 1014–1022. <https://doi.org/10.1038/ni.2703>
4. Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023). Cancer-associated fibroblasts: from basic science to anticancer therapy. *Experimental & Molecular Medicine*, 55(7), 1322–1332. <https://doi.org/10.1038/s12276-023-01013-0>
5. Jia, Q., Wang, A., Yuan, Y., Zhu, B., & Long, H. (2022). Heterogeneity of the tumor immune microenvironment and its clinical relevance. *Experimental Hematology and Oncology*, 11(1). <https://doi.org/10.1186/s40164-022-00277-y>

6. Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024). Regulatory mechanisms of PD-1/PD-L1 in cancers. *Molecular Cancer*, 23(1). <https://doi.org/10.1186/s12943-024-02023-w>
7. Li, C., Yu, X., Han, X., Lian, C., Wang, Z., Shao, S., Shao, F., Wang, H., Ma, S., & Liu, J. (2024). Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy. *iScience*, 27(9), 110750. <https://doi.org/10.1016/j.isci.2024.110750>
8. (N.d.-b). Sciencedirect.com. Retrieved July 9, 2025, from <https://www.sciencedirect.com/science/article/pii/S2352304224002393#:~:text=Cytokines%20and%20chemokines%20emerge%20as,milieu%20of%20the%20EC%20TME.&text=These%20signaling%20molecules%20play%20a,tumor%20and%20the%20immune%20system>.
9. Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021). Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients a
10. d a new challenge for internists and general practitioners. *Cancer Metastasis Reviews*, 40(3), 949–982. <https://doi.org/10.1007/s10555-021-09976-0>
11. (N.d.). Researchgate.net. Retrieved July 9, 2025, from https://www.researchgate.net/figure/Immune-evasion-mechanisms-in-the-tumor-microenvironment-TME-A-Immune-checkpoint_fig4_387927657
12. Monjazez, A. M., Zamora, A. E., Grossenbacher, S. K., Mirsoian, A., Sckisel, G. D., & Murphy, W. J. (2013). Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. *Frontiers in Oncology*, 3, 197. <https://doi.org/10.3389/fonc.2013.00197>
13. National Cancer Institute. Immune Checkpoint Inhibitors [Internet]. National Cancer Institute. 2022. Available from: <https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors>

14. Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. *Biomedicine & Pharmacotherapy* [Internet]. 2023 Aug 1 [cited 2023 Dec 17];164(114954):114954. Available from: <https://www.sciencedirect.com/science/article/pii/S0753332223007448#bib103>
15. Yang Z, Ma Y, Zhao H, Yuan Y, Kim BYS. Nanotechnology platforms for cancer immunotherapy. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* [Internet]. 2020;12(2):e1590. Available from: <http://dx.doi.org/10.1002/wnan.1590>
16. Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025). Resistance mechanisms to
19. Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang, J. Y., Konno, H., Guo, X., Ye, Y., Gao, S., Wang, S., Hu, X., Ren, X., Shen, Z., Ouyang, W., & Zhang, Z. (2018). Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. *Nature*, 564(7735), 268–272.
- immune checkpoint inhibitors: updated insights. *Molecular Cancer*, 24(1). <https://doi.org/10.1186/s12943-024-02212-7>
17. Medina, T., MD. (2025, July 3). Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL therapy in Advanced Melanoma. *OncLive*. <https://www.onclive.com/view/dr-medina-on-the-long-term-efficacy-and-safety-of-lifileucel-til-therapy-in-advanced-melanoma>
18. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. *Science*, 359(6382), 1350–1355. <https://doi.org/10.1126/science.aar4060>
- <https://doi.org/10.1038/s41586-018-0694-x>
20. Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. *Science*, 348(6230), 69–74. <https://doi.org/10.1126/science.aaa4971>